Bone Morphogenetic Protein Delivery Systems
- 1 August 2002
- journal article
- review article
- Published by Wolters Kluwer Health in Spine
- Vol. 27 (Supplement), S16-S23
- https://doi.org/10.1097/00007632-200208151-00005
Abstract
A review was conducted. To review the rationale for the use of carrier systems to deliver bone morphogenetic proteins to sites of orthopedic repair, and to discuss commonly used carriers. Carriers for bone morphogenetic protein in spine fusion are used to increase the retention of these osteogenic factors at the treatment site, and to serve as an osteoconductive matrix for bone forming cells while maintaining a space or volume in which bone formation can occur. The literature is reviewed and discussed. Although bone morphogenetic proteins can induce bone formation when delivered in formulation buffer in small animal models, carriers often are used in larger animal models and human clinical trials to maintain the concentration of osteogenic factors at the treatment site for a sufficient period to allow bone-forming cells to migrate to the area of injury and to proliferate and differentiate. For spine fusion, carriers also are required to serve as an osteoconductive matrix for bone-forming cells while maintaining a space or volume in which bone formation can occur. Four major categories of carrier materials are used for osteogenic factor delivery: inorganic materials, synthetic polymers, natural polymers, and composites of the first three materials. In addition, allograft bone has been used to deliver osteogenic factors to the site of orthopedic repairs. The efficacy of osteogenic carrier combinations often is site specific and species specific. The requirement for supraphysiologic concentrations of osteogenic factors may be related to the ability of the delivery system to increase the retention time at the treatment site and overcome tight regulation of these factors by their inhibitors. Dose escalation in large animal models also may be related to a decrease in the number of responding cells and a slower rate of bone formation. New delivery systems being evaluated include depot delivery systems, viral vector systems, conjugated osteogenic factor delivery systems, and oral small molecule targets. Delivery systems play an important role in the use of osteogenic factors to augment spine fusions and other orthopedic repairs.Keywords
This publication has 67 references indexed in Scilit:
- Demineralized bone matrix, bone morphogenetic proteins, and animal models of spine fusion: an overviewEuropean Spine Journal, 2001
- The Bone Morphogenetic Proteins Antagonist Noggin Inhibits Membranous OssificationJournal of Bone and Mineral Research, 2001
- Experimental anterior spine fusion using bovine bone morphogenetic protein: a study in rabbitsJournal of Orthopaedic Science, 2000
- Evaluation of recombinant human bone morphogenetic protein‐2 as a bone‐graft substitute in a canine segmental defect modelJournal of Orthopaedic Research, 2000
- Regional gene therapy with a BMP‐2‐producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodentsJournal of Orthopaedic Research, 1998
- Role of Bone SubstitutesClinical Orthopaedics and Related Research, 1996
- Regulation of Bone Formation by Bone Morphogenetic Proteins and Other Growth FactorsClinical Orthopaedics and Related Research, 1996
- Healing of large segmental defects in rat femurs is aided by RhBMP‐2 in PLGA matrixJournal of Biomedical Materials Research, 1994
- Polylactic Acid-Polyethylene Glycol Block CopolymerClinical Orthopaedics and Related Research, 1993
- Ectopic induction of cartilage and bone by water‐soluble proteins from bovine bone using a polyanhydride delivery vehicleJournal of Biomedical Materials Research, 1990